

# JSH-23

Catalog No: **tcsc2317**



## Available Sizes

**Size:** 5mg

**Size:** 10mg



## Specifications

**CAS No:**

749886-87-1

**Formula:**

$C_{16}H_{20}N_2$

**Pathway:**

NF-κB

**Target:**

NF-κB

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 56$  mg/mL (233.00 mM)

**Observed Molecular Weight:**

240.34

## Product Description


JSH-23 is a **NF-κB** inhibitor with an **IC<sub>50</sub>** of 7.1 μM in LPS-stimulated macrophages RAW 264.7 cells. JSH-23 inhibits LPS-induced nuclear translocation of NF-κB p65 without affecting IκB degradation.

IC50 & Target: IC50: 7.1 μM (NF-κB)

**In Vitro:** JSH-23 inhibits lipopolysaccharide (LPS)-induced chromatin condensation in a dose-dependent manner, corresponding to

44±4% inhibition at 3 μM, 63±5% at 10 μM and 93±3% at 30 μM<sup>[1]</sup>. JSH-23 (5, 10, and 15 μM) significantly reduces mean neuronal migration in LPS-activated cells<sup>[2]</sup>. Co-treatment of A2780 cells with JSH-23 and clinically ineffective transplatin at their IC<sub>50</sub> concentrations (130 μM transplatin and 20 μM JSH-23) for 72 h also causes a more pronounced decrease in cell viability compared to the effects of transplatin or JSH-23 alone<sup>[3]</sup>.

***In Vivo:*** JSH-23 (1 and 3 mg/kg, p.o.) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic animals and decreases the nerve lipid peroxidation, partially replenishes the depleted levels of GSH in nerve of diabetic rats<sup>[4]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!